Boehringer Ingelheim announced that SPIRIVA® RESPIMAT® is now available for the treatment of asthma by prescription in U.S. pharmacies. The U.S. Food and Drug Administration (FDA) approved a once-daily dose of 2.5 µg for the long-term maintenance treatment of asthma in people ages 12 and older.
People with asthma who continue to experience symptoms during the course of a week have a six times greater chance of having an asthma flare-up in the following few weeks than those with minimal to no daytime symptoms. These persistent symptoms can have a negative impact on the ability to perform daily activities for people living with asthma.
Unlike other asthma daily maintenance treatments, SPIRIVA® RESPIMAT® is from a new class of medications in asthma known as long-acting anticholinergics, the first new class of inhaled medicine approved in over 10 years for asthma.
SPIRIVA® RESPIMAT® in asthma is delivered by RESPIMAT®, the inhaler which actively‡ delivers a unique mist, meaning the patient just needs to breathe in naturally for the medication to go deep into the lungs.
The FDA approved SPIRIVA® RESPIMAT® for the treatment of asthma based on efficacy and safety data from a comprehensive clinical trial program, including 12 trials of approximately 5,000 adults and adolescents with mild, moderate and severe symptomatic asthma on at least an inhaled corticosteroid (ICS).
